April 14, 2021
The immunotherapy agent pembrolizumab can provide clinical benefit to some patients with metastatic breast cancer whose tumors were found to have a high number of mutations, and whose cancer continued to progress with standard treatments. That’s according to newly published results from ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) study. […]
